RNTX (Rein Therapeutics) Beta: 2.0735 (As of Jun. 24, 2026)


RNTX Rein Therapeutics Inc RNTX
30 GF Score
Price $1.01
! 1 Warning Sign
View Full Analysis

What is Rein Therapeutics Beta?

Rein Therapeutics RNTX +3.12% 30 Beta is 2.0735 as of Jun. 24, 2026. GuruFocus rates RNTX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), Rein Therapeutics's Beta is 2.0735.


Rein Therapeutics  (NAS:RNTX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Rein Therapeutics Beta Related Terms


Rein Therapeutics Beta Historical Data

* Premium members only.

The historical data trend for Rein Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rein Therapeutics Beta Chart

Rein Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.40 1.76 1.43 1.89 3.32

Rein Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.76 1.43 2.53 3.32 2.29

RNTX vs ATRA, OSTX, IBIO: Beta Comparison

For the Biotechnology subindustry, Rein Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rein Therapeutics Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rein Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Rein Therapeutics's Beta falls into.


RNTX
30GF Score
Rein Therapeutics Inc RNTX
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rein Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 2.0735 mean?
Rein Therapeutics (RNTX) has a Beta of 2.0735 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Rein Therapeutics and its competitors.
Is Rein Therapeutics' Beta too high?
Rein Therapeutics' current Beta is 2.0735. Overall, Rein Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Rein Therapeutics' Beta compare to ATRA and OSTX?
Rein Therapeutics' Beta of 2.0735 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Rein Therapeutics and its competitors. Rein Therapeutics's current Beta is 2.0735. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rein Therapeutics stock overvalued right now?
Rein Therapeutics (RNTX) has a current Beta of 2.0735. The current Beta is 2.0735. Rein Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Rein Therapeutics (RNTX), the current Beta is 2.0735 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rein Therapeutics Business Description

Address 12407 North Mopac Expressway, Suite 250, No.390, Austin, TX, USA, 78758
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
30GF Score

Get the complete analysis for RNTX

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.01
Price